TrialSignal
Clinical trial intelligence report
Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05016349
Status
UNKNOWN
Phase
Phase II
Sponsor
Mahmoud Ramadan mohamed Elkazzaz
Executive brief
Investment-Ready Snapshot
This clinical trial investigates a novel quadrate combination therapy involving Mifepristone, Tamoxifen, Retinoic Acid, and Cannabidiol for treating early breast cancer. The study aims to evaluate the anti-tumor activity of this combination and its effects on CK5-expressing cells, addressing therapy resistance in ERα-positive breast cancer.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05016349
Indication
Breast Cancer Female
Modality
small molecule
Target
Breast Cancer
Intervention
All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, 9 cis retinoic acid, Tamoxifen, Standard therapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.